current methods for prostate cancer diagnosis. The researchers found
that PCA3 scores correlate with the probability of positive prostate
biopsies, and that PCA3 scores are independent of prostate volume,
serum PSA level and number of prior biopsies. In the second article,
"PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor
Volume: Implication in Selecting Candidates for Active Surveillance"
(Volume 179, Issue 5, Pages 1804-1810, May 2008), researchers from the
MD Anderson Cancer Center and Gen-Probe conclude that PCA3 scores
correlate with both tumor volumes and prostatectomy Gleason scores,
both of which are measures of prostate cancer aggressiveness. As a
result, they suggest that PCA3 may have clinical applicability in
identifying men who have low-volume or low-grade prostate cancer.
Webcast Conference Call
A live webcast of Gen-Probe's first quarter 2008 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (866) 421-6934 for domestic callers and (203) 369-0825 for international callers.
Gen-Probe Incorporated is a global leader in the development,
manufacture and marketing of rapid, accurate and cost-effective nucleic
acid tests (NATs) that are used primarily to diagnose human diseases and
screen donated human blood. Gen-Probe has approximately 25 years of NAT
expertise, and received the 2004 National Medal of Technology, America's
highest honor for technological innovation, for developing NAT assays for
blood screening. Gen-Probe is headquartered in San Diego and employs
approximately 1,000 people. For more i
|SOURCE Gen-Probe Incorporated|
Copyright©2008 PR Newswire.
All rights reserved